(Q36528048)

English

The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization

scientific article published on 2 February 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

author name string

Lei Liu

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Yan Zhao

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Jia Jia

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Hui Chen

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Wei Bai

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Man Yang

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Zhanxin Yin

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Chuangye He

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Lei Zhang

9

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Wengang Guo

10

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Jing Niu

11

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Jie Yuan

12

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Hongwei Cai

13

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Jielai Xia

14

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Daiming Fan

15

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Guohong Han

16

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

language of work or name

0 references

publication date

2 February 2016

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Scientific Reports

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

19851

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

copyright license

Creative Commons Attribution 4.0 International

2 February 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

Management of HCC

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

Management of hepatocellular carcinoma: An update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

A model to predict survival in patients with end-stage liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

alpha-fetoprotein in noneoplastic hepatic disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

30 September 2017

Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

28 June 2018

Response assessment methodologies in hepatocellular carcinoma: complexities in the era of local and systemic treatments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

21 September 2018

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

21 September 2018

Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

21 September 2018

Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4735679

21 September 2018

Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation

1 reference

https://pubmed.ncbi.nlm.nih.gov/26831408

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization

1 reference

https://pubmed.ncbi.nlm.nih.gov/26831408

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26831408

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Global battle against cancer won't be won with treatment alone--effective prevention measures urgently needed to prevent cancer crisis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26831408

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26831408

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres

1 reference

https://pubmed.ncbi.nlm.nih.gov/26831408

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/26831408

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SREP19851

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36528048&oldid=2199002314"